Lupus Erythematosus, Systemic
Conditions
Brief summary
The overall aim of this project is to investigate the different types of immune cells found in the blood of patients with Systemic Lupus Erythematosus (SLE) and healthy donors. We know that the amount of fat on the surface of immune cells is an important factor controlling their behaviour. Immune cells from SLE patients are defective and this is associated with changes in the levels of fat on these cells. This project will investigate the level of fat in the blood and on immune cells from patients with SLE and age matched healthy controls, and measure how changes in the amount of fat can affect the way immune cells behave.
Detailed description
Accelerated atherosclerosis is a serious complication of autoimmunity including patients with both adult and juvenile onset systemic lupus erythematosus (SLE). This suggests that defects in fat levels could contribute to disease pathogenesis. The immune system in patients with SLE does not work normally. In adult patients with SLE we know that many of the immune cells involved in protecting the body from infections or cancer are over-active and actually cause disease. In young people the immune system is still developing and very little is known about what goes wrong in patients that develop juvenile-onset SLE, whether this is the same as adult disease and whether the same treatments are relevant for this group of patients. This project aims to find out whether immune cells from SLE patients with adult-onset disease have the same defects as adult patients with juvenile-onset SLE. We know that an important factor that controls immune cell behaviour is the amount of fat that they have on their surface. We also know that a change in fat on immune cells from adult patients with SLE makes them defective. This project will investigate the level of fat in the blood and in immune cells from adult patients with juvenile-onset SLE and age matched healthy controls, and measure how changes in the amount of fat can affect the way immune cells behave. We will investigate how drugs that control fat levels can help to normalize the behaviour of immune cells from SLE patients.
Interventions
OTHERBlood sampling to include Deoxyribonucleic Acid (DNA) and Ribonucleic Acid (RNA)
* Blood sampling to measure immune cell phenotypes and examine DNA/RNA and identify serum biomarkers. * Food Frequency Questionnaires (FFQs) and/or diet recall questionnaires to assess dietary intake. * Cardiovascular Ultrasound Scans (USS) to measure how well blood is carried around the body.
Sponsors
University College London Hospitals
University College, London
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Inclusion criteria
* Diagnosis of SLE according to American College of Rheumatology revised criteria * Having given written informed consent prior to undertaking any study-related procedures. * Male and female patients between the ages of 18 and 80 years. Patients who have met all the above inclusion criteria listed and healthy donors will be screened for the following
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Collection of blood samples | 4 hours from point of sample collection | Blood sampling to measure immune cell phenotypes and examine DNA/RNA and identify serum biomarkers. |
| Completion of FFQ's and/or diet recall questionnaires | Same day as recruited to study. | FFQ's and/or diet recall questionnaires to assess dietary intake |
| Cardiovascular Ultrasound scans (USS) | Within 2 months from recruitment. | USS of Intima Media Thickness (IMT), Flow Mediated Dilatation (FMD), Pulse Wave Velocity (PWV) and Laser Doppler Flowmetry measurement. As part of the procedure, sub lingual administration of GTN spray will be administered to measure FMD. |
Countries
United Kingdom
Contacts
Primary ContactLiz Jury, Prof
Backup ContactGeorge Robinson, Dr
Outcome results
None listed